A Phase 1 Study of BMS-986453 CAR T Cell Therapy in People With Multiple Myeloma


Full Title

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma


Researchers want to find the best dose of BMS-986453 to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.

BMS-986453 is a form of chimeric antigen receptor (CAR) T cell therapy, a type of cellular immunotherapy. With CAR T cell therapy, white blood cells called T cells are removed from your body. The T cells are altered in a lab to recognize proteins on your cancer cells. They are then multiplied to larger numbers and returned to your body to find and destroy cancer cells.

BMS-986453 targets proteins called BCMA and GPRC5D on myeloma cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that came back or keeps growing even after treatment.
  • Have recovered from the serious side effects of previous therapies before getting BMS-986453.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID